For information regarding COVID-19 and updated visitation guidelines, please click here.

Oncology Clinical Trials

Call for more information: 770-219-9010

Explore our current clinical trials for oncology:

All Tumor Types

AMGEN OnPRO

Ph 4 Neulasta 20170758 A Prospective Study Comparing the Effectiveness of Neulasta® (pegfilgrastim) Onpro to Other Physician Choices for Prophylaxis of Febrile Neutropenia in Subjects with Non-myeloid Malignancies at High Risk for Febrile Neutropenia.

Clinical Trials

DCP-001

Use of a clinical trial screening tool to address cancer health disparities in the nci community oncology research program (ncorp).

Link

EAY131-MATCH

Molecular analysis for therapy choice (nci-match)

Link

PRO 02-MY PATHWAY

An Open-Label, Phase IIa Study Evaluating Trastuzumab,/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib and Atezolizumab in patients who have advanced solid tumors with mutations predictive of response to one of these agents.

Link

Brain

A221101

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma .

Link

BRE 203

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR).

Link

S1207

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and her2/neu negative breast cancer.

Link

Breast

EA1151

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)(no malignancy.

S1501

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III.

S1418

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy.

Colorectal

S0820-PACES

A double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenoma and second primary colorectal cancers in patients with stage 0-III colon cancer, phase III.

Link

NRG-GI004

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.

NRG-GI005_COBRA

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA).

GYN

724

Phase Iii randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy.

Link

GOG 0238

ArRandomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus.

Link

GOG 0225

Can diet and physical activity modulate ovarian, fallopian tube and primary peritoneal cancer progression-free survival?

Link

GOG 0263

Randomized phase iii clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage i/iia cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy.

Link

GOG 3015 (YO39523)

A phase III, multicenter, randomized, study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage iii or stage iv ovarian, fallopian tube, or primary peritoneal cancer.

Link

NRG-GY009

A randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer.

Novocure_GOG-3029_INNOVATE-3

A pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC).

Lung

A151216 (ALCHEMIST-Main)

Adjuvant lung cancer enrichment marker identification and sequencing trial (alchemist).

Link

A081105 (ALCHEMIST Component)

Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (egfr) mutant non-small cell lung cancer (nsclc)).

Link

AZ PACIFIC 6

A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer

Clinical Trials

S1400

Phase II/III biomarker-driven master protocol for second line therapy of squamous cell lung cancer.

Link

S1400F

A phase II study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY).

Link

S1400G

A phase II study of talazoparib (bmn 673) in patients with homologous recombination repair deficiency positive stage iv squamous cell lung cancer (lung-map sub-study).

Link

S1400K

A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG- MAP SUB-STUDY)

Link

S1800A (Non-BiomarkerDriven Sub-Study)

Ph II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).

S1900A (BiomarkerDriven Sub-Study)

A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study).

S1900BDSS (BiomarkerDriven Sub-Study)

A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Screening Sub-study).

S1900C (BiomarkerDriven Sub-Study)

A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-study).

NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) study (suspected or MDS/MPN undergoing bone marrow assessments).

Link

E4512 (ALCHEMIST Component)

A phase iii double-blind trial for surgically resected early stage non-small cell lung cancer: crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (alk) fusion protein.

Link

EA5142 (ALCHEMIST Component)

Adjuvant nivolumab in resected lung cancers (anvil) - a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers.

Link

EA5163_S1709 INSIGNA

A randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis.

LUNGMAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).

Prostate

924

Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase III randomized trial.

Link

 

 

[Updated: 5/27/2020]

 

 

Copyright ©2020 Northeast Georgia Health System, Inc. | 743 Spring Street Gainesville, GA 30501 | (770) 219-9000